Drug facts
Semaglutide and hair loss
Quick answer
It is in the label. 3% of participants on semaglutide 2.4 mg reported it, against 1% on placebo — so 2 in 100 is what the drug itself added.
How common it was1
Hair loss is in the label's table, near the bottom of the reactions reported in 2% or more of participants. It is far less common than the gastrointestinal reactions above it, and it is listed — which is worth saying, because a great deal of writing on this question treats it as anecdote.
| Arm | Reported it |
|---|---|
| Semaglutide 2.4 mg | 3% |
| Placebo | 1% |
Three in a hundred against one in a hundred is a real difference and a small number. Both facts belong in the answer: it is not imagined, and it is not what happens to most people.
What the label does not say1
It does not say why. The trials recorded that participants reported it; they did not establish a mechanism, and the label offers none. The widely repeated explanation — that rapid weight loss of any cause can push hair follicles into a shedding phase — is not something this label states, so this page does not state it either.
What this page is not
This reports what the approved label recorded, and offers no management advice — that is your prescriber’s decision. Nor is it a measurement of a compounded vial: no compounded preparation has run a trial of its own. The full table is on side effects.
Sources
- FDA prescribing information for WEGOVY (semaglutide), section 6.1, revision 6/2026 DailyMed